Each ml of concentrate contains 20 mg of natalizumab.
Natalizumab is a recombinant humanised anti-α4-integrin antibody produced in a murine cell line by recombinant DNA technology.
When diluted (see Special precautions for disposal and other handling under Cautions for Usage), the solution for infusion contains approximately 2.6mg/ml of natalizumab.
Excipient with known effect: Each vial contains 2.3 mmol (or 52 mg) sodium. When diluted in 100 ml sodium chloride 9 mg/ml (0.9%) the medicinal product contains 17.7mmol (or 406 mg) sodium.
Excipients/Inactive Ingredients: Sodium phosphate, monobasic, monohydrate; Sodium phosphate, dibasic, heptahydrate; Sodium chloride; Polysorbate 80 (E433); Water for injections.